Showing posts with label scientists. Show all posts
Showing posts with label scientists. Show all posts

Saturday, September 10, 2011

Scientists induce hibernation at will: Discovery puts scientists closer to human application

ScienceDaily (July 26, 2011) — Hibernation is an essential survival strategy for some animals and scientists have long thought it could also hold promise for human survival. But how hibernation works is largely unknown. Scientists at the University of Alaska Fairbanks have successfully induced hibernation at will, showing how the process is initiated. Their research is published in the July 26 issue of The Journal of Neuroscience.See Also:Health & MedicineInsomnia ResearchControlled SubstancesHuman BiologyPlants & AnimalsBiologyAnimalsNatureStrange ScienceReferenceParasympathetic nervous systemExcitotoxicity and cell damageNeurotransmitterAntifreeze protein

A hibernating animal has a reduced heart rate and blood flow similar to a person in cardiac arrest, yet the hibernator doesn't suffer the brain damage that can occur in people. "Understanding the neuroprotective qualities of hibernating animals may lead to development of a drug or therapy to save people's lives after a stroke or heart attack," said Kelly Drew, senior author and UAF professor of chemistry and biochemistry in the Institute of Arctic Biology.

Hibernating animals survive by severely reducing their metabolism, a condition called torpor, in which oxygen consumption can fall to as low as one percent of resting metabolic rate and core body temperature to near or below freezing temperatures.

Arctic ground squirrels, like all animals and people, produce a molecule called adenosine that slows nerve cell activity. "When a squirrel begins to hibernate and when you feel drowsy it's because adenosine molecules have attached themselves to receptors in your brain," said Tulasi Jinka, lead author and IAB post-doctoral fellow in Drew's lab.

The receptors can be regulated by a simple cup of coffee. A caffeine molecule is similar enough in structure to adenosine that it binds to the receptors and effectively stops or reverses the onset of drowsiness. Jinka and Drew wanted to know what substances trip the squirrels' switch to start to hibernate.

"We devised an experiment in which non-hibernating arctic ground squirrels were given a substance that stimulated adenosine receptors in their brains. We expected the substance to induce hibernation," Drew said. "We also gave a substance similar to caffeine to arouse hibernating ground squirrels."

The non-hibernating squirrels were tested three times during one year. They were tested during the summer when they were not hibernating, again early in their hibernation season and a third time mid-way through the hibernation season. If animals were hibernating before the test Jinka woke them up to see if the substance would cause them to go back into hibernation. To ensure that his expectations did not influence the results he delivered a placebo in the same manner as the drug and did not know which solution contained the active substance when he conducted the experiments.

Torpor was induced in all six of the squirrels awoken during mid-hibernation season, but in only two of the six from the early hibernation season group and in none during the summer season. The caffeine-like substance reversed torpor in all of the hibernating squirrels.

"We show for the first time that activation of the adenosine receptors is sufficient to induce torpor in arctic ground squirrels during their hibernation season," Jinka said, who conducted this experiment while he was a graduate student.

What Jinka and Drew don't yet know is how season causes the receptors to become increasingly sensitive to adenosine as the time of hibernation progresses.

Jinka and Drew are expanding their adenosine research to rats, which more closely resemble the physiology of humans. "Rats allow us to move toward being able to apply this research to humans," Jinka said.

Email or share this story:

Wednesday, August 31, 2011

Minority rules: Scientists discover tipping point for the spread of ideas

ScienceDaily (July 25, 2011) — Scientists at Rensselaer Polytechnic Institute have found that when just 10 percent of the population holds an unshakable belief, their belief will always be adopted by the majority of the society. The scientists, who are members of the Social Cognitive Networks Academic Research Center (SCNARC) at Rensselaer, used computational and analytical methods to discover the tipping point where a minority belief becomes the majority opinion. The finding has implications for the study and influence of societal interactions ranging from the spread of innovations to the movement of political ideals.See Also:Mind & BrainSocial PsychologyRelationshipsComputers & MathComputer ModelingMathematical ModelingScience & SocietyEthicsPolitical ScienceLiving WellStrange ScienceReferenceCognitive biasFunctional neuroimagingIntuition (knowledge)Culture of fear

"When the number of committed opinion holders is below 10 percent, there is no visible progress in the spread of ideas. It would literally take the amount of time comparable to the age of the universe for this size group to reach the majority," said SCNARC Director Boleslaw Szymanski, the Claire and Roland Schmitt Distinguished Professor at Rensselaer. "Once that number grows above 10 percent, the idea spreads like flame."

As an example, the ongoing events in Tunisia and Egypt appear to exhibit a similar process, according to Szymanski. "In those countries, dictators who were in power for decades were suddenly overthrown in just a few weeks."

The findings were published in the July 22, 2011, early online edition of the journal Physical Review E in an article titled "Social consensus through the influence of committed minorities."

An important aspect of the finding is that the percent of committed opinion holders required to shift majority opinion does not change significantly regardless of the type of network in which the opinion holders are working. In other words, the percentage of committed opinion holders required to influence a society remains at approximately 10 percent, regardless of how or where that opinion starts and spreads in the society.

To reach their conclusion, the scientists developed computer models of various types of social networks. One of the networks had each person connect to every other person in the network. The second model included certain individuals who were connected to a large number of people, making them opinion hubs or leaders. The final model gave every person in the model roughly the same number of connections. The initial state of each of the models was a sea of traditional-view holders. Each of these individuals held a view, but were also, importantly, open minded to other views.

Once the networks were built, the scientists then "sprinkled" in some true believers throughout each of the networks. These people were completely set in their views and unflappable in modifying those beliefs. As those true believers began to converse with those who held the traditional belief system, the tides gradually and then very abruptly began to shift.

"In general, people do not like to have an unpopular opinion and are always seeking to try locally to come to consensus. We set up this dynamic in each of our models," said SCNARC Research Associate and corresponding paper author Sameet Sreenivasan. To accomplish this, each of the individuals in the models "talked" to each other about their opinion. If the listener held the same opinions as the speaker, it reinforced the listener's belief. If the opinion was different, the listener considered it and moved on to talk to another person. If that person also held this new belief, the listener then adopted that belief.

"As agents of change start to convince more and more people, the situation begins to change," Sreenivasan said. "People begin to question their own views at first and then completely adopt the new view to spread it even further. If the true believers just influenced their neighbors, that wouldn't change anything within the larger system, as we saw with percentages less than 10."

The research has broad implications for understanding how opinion spreads. "There are clearly situations in which it helps to know how to efficiently spread some opinion or how to suppress a developing opinion," said Associate Professor of Physics and co-author of the paper Gyorgy Korniss. "Some examples might be the need to quickly convince a town to move before a hurricane or spread new information on the prevention of disease in a rural village."

The researchers are now looking for partners within the social sciences and other fields to compare their computational models to historical examples. They are also looking to study how the percentage might change when input into a model where the society is polarized. Instead of simply holding one traditional view, the society would instead hold two opposing viewpoints. An example of this polarization would be Democrat versus Republican.

The research was funded by the Army Research Laboratory (ARL) through SCNARC, part of the Network Science Collaborative Technology Alliance (NS-CTA), the Army Research Office (ARO), and the Office of Naval Research (ONR).

The research is part of a much larger body of work taking place under SCNARC at Rensselaer. The center joins researchers from a broad spectrum of fields -- including sociology, physics, computer science, and engineering -- in exploring social cognitive networks. The center studies the fundamentals of network structures and how those structures are altered by technology. The goal of the center is to develop a deeper understanding of networks and a firm scientific basis for the newly arising field of network science. More information on the launch of SCNARC can be found at http://news.rpi.edu/update.do?artcenterkey

Saturday, August 27, 2011

Scientists complete first mapping of molecule found in human embryonic stem cells

ScienceDaily (July 21, 2011) — Stem cell researchers at UCLA have generated the first genome-wide mapping of a DNA modification called 5-hydroxymethylcytosine (5hmC) in embryonic stem cells, and discovered that it is predominantly found in genes that are turned on, or active.See Also:Health & MedicineGenesStem CellsHuman BiologyBrain TumorProstate CancerLymphomaReferenceBRCA1Tumor suppressor geneEmbryonic stem cellDNA microarray

The finding by researchers with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA may prove to be important in controlling diseases like cancer, where the regulation of certain genes plays a role in disease development.

"Any way you can control genes will be hugely important for human disease and cancer," said Steven E. Jacobsen, a professor of molecular, cell and developmental biology in the Life Sciences and a Howard Hughes Medical Institute investigator. "Cancer is generally a problem of genes being inappropriately turned off or mutated, like tumor suppressors genes, or genes that should be off getting switched on."

The study appears in the July issue of the journal Genome Biology.

5hmC is formed from the DNA base cytosine by adding a methyl group and then a hydroxy group. The molecule is important in epigenetics -- the study of changes in gene expression caused by mechanisms other than changes in the DNA sequence -- because the newly formed hydroxymethyl group on the cytosine can potentially switch a gene on and off, Jacobsen said.

The molecule 5hmC was only recently discovered, and its function has not been clearly understood, Jacobsen said. Until now, researchers didn't know where 5hmC was located within the genome.

"That is important to know because it helps you to understand how it is functioning and what it's being used for," said Jacobsen, who also is a researcher with UCLA's Jonsson Comprehensive Cancer Center. "We had known that DNA could be modified by 5hmC, but it wasn't clear where on the genome this was occurring."

Jacobsen, whose lab studies the molecular genetics and genomics of DNA methylation patterning, used genomics to define where in human embryonic stem cells the 5hmC was present. They used human embryonic stem cells because it had been shown previously that the molecule is abundant in those cells, as well as in brain cells, Jacobsen said.

In the study, Jacobsen found that 5hmC was associated with genes and tended to be found on genes that were active. The study also revealed that 5hmC was present on a type of DNA regulatory element, called enhancers, which help control gene expression. In particular, 5hmC was present on enhancers that are crucial for defining the nature of the human embryonic stem cells.

The results suggest that 5hmC plays a role in the activation of genes. This is opposite of the role of the more well studied 5mC (DNA methylation), which is involved in silencing genes. This relationship is in line with the view that 5hmC is created directly from 5mC.

"If we can understand the function of 5hmC, that will lead to greater understanding of how genes are turned on and off and that could lead to the development of methods for controlling gene regulation," Jacobsen said.

Moving forward, Jacobsen and his team will seek to uncover the mechanism by which 5hmC is created from DNA methylation and how it becomes localized to particular areas of the genome, such as the enhancers.

The two-year study was funded by the Howard Hughes Medical Institute, a Fred Eiserling and Judith Lengyel Graduate Doctoral Fellowship, the Leukemia & Lymphoma Society, the National Institutes of Health and by an Innovation Award from the Eli and Edythe Broad Center of Regenerative Medicine & Stem Cell Research at UCLA.

Email or share this story:

Tuesday, August 23, 2011

Scientists developing new therapy for HER2-positive breast cancer

ScienceDaily (July 26, 2011) — Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research, a journal of the American Association for Cancer Research.See Also:Health & MedicineBreast CancerCancerBrain TumorLung CancerOvarian CancerSkin CancerReferenceBreast cancerMonoclonal antibody therapyMetastasisNanomedicine

Jacek Capala, Ph.D., D.Sc., an investigator at the National Cancer Institute, and colleagues designed, produced and tested HER2-Affitoxin, a novel protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38.

"Unlike the current HER2-targeted therapeutics, such as Herceptin, this protein does not interfere with the HER2 signaling pathway but, instead, uses HER2 as a target to deliver a modified form of bacterial toxin specifically to the HER2-positive cancer cells. When cells absorb the toxin, it interferes with protein production and, thereby, kills them," said Capala.

At least, that is what happened in Capala's laboratory. After Affitoxin was injected into tumor-bearing mice, even relatively large, aggressive tumors stopped growing and most of them disappeared. The effect was strong enough that Capala believes it warrants a clinical trial.

"Herceptin has revolutionized the treatment of patients with HER2-positive breast cancer, but a significant number of tumors acquire resistance to the drug," said Capala. "Affitoxin could offer another therapeutic option for those patients whose tumors no longer respond to Herceptin."

Email or share this story:

Thursday, August 18, 2011

Scientists discover potential stroke treatment that may extend time to prevent brain damage

ScienceDaily (July 25, 2011) — A naturally occurring substance shrank the size of stroke-induced lesions in the brains of experimental mice -- even when administered as much as 12 hours after the event, Stanford University School of Medicine researchers have shown. The substance, alpha-B-crystallin, acts as a brake on the immune system, lowering levels of inflammatory molecules whose actions are responsible for substantial brain damage above and beyond that caused by the initial oxygen deprivation of a stroke.See Also:Health & MedicineStroke PreventionHeart DiseaseElder CareMind & BrainBrain InjuryStrokeCaregivingReferenceMulti-infarct dementiaBrain damageStrokeNeurology

The finding, which will be published online July 25 in Proceedings of the National Academy of Sciences, is of great potential significance. Every year brings nearly 800,000 new stroke patients in North America. "That's one every 40 seconds," said Gary Steinberg, MD, PhD, director of Stanford's Institute for Neuro-Innovation and Translational Neurosciences and one of the study's two senior authors. Steinberg is also the Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and the Neurosciences, and chair of neurosurgery at the medical school.

The largest single cause of severe neurological disability and the third-leading cause of death in the United States, stroke accounts for an estimated $74 billion annually in related costs, including treatment and additional assistance for the three of every four stroke patients whose ability to perform the activities of daily life is impaired. Strokes are caused by a sudden drop in the flow of blood to the brain resulting from a clot or, less often, bleeding. One of every three stroke patients is under the age of 65. In all, there are 5.4 million stroke survivors in the United States and 15 million worldwide.

The only currently approved drug for stroke -- tissue plasminogen activator, or tPA -- dissolves clots that keep oxygenated blood from reaching brain tissue. To be effective, tPA must be administered within about 4.5 hours after the stroke. But patients' brains must first be scanned to rule out the possibility that the stroke was caused by bleeding, which tPA would exacerbate, rather than by blockage.

Moreover, tPA does nothing to counter the stroke's insidious inflammatory aftershock: a flood of noxious chemicals secreted by angry immune cells that rush in to the affected area, causing significant further damage.

Alpha-B-crystallin appears to act as a sponge, sopping up those bad actors and stopping inflammation from making a bad situation worse.

Alpha-B-crystallin is a major structural protein in the eye's lens. It is also constantly made in the heart. In other tissues, including the brain, its production can be triggered by stressful events, such as oxygen deprivation or excessive heat or cold. Growing evidence suggests that alpha-B-crystallin can help curb inflammatory activity in the brain.

"The brain doesn't roll over and play dead when it's under attack," said Lawrence Steinman, MD, the other senior author of the new study, who is the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics as well as chair of Stanford's interdepartmental program in immunology.

In an earlier study, published in Nature in 2007, Steinman and his colleagues found that the presence of alpha-B-crystallin could help reduce the severity of brain damage caused by multiple sclerosis, a chronic, debilitating autoimmune disease of the brain. Other studies published this year by his group have shown that alpha-B-crystallin limits the damage caused by blood-supply cutoffs to heart tissue and the retina.

It seemed logical to see if this protein could mitigate the effects of a stroke. "We made a jump from its relevance in inflammatory diseases such as multiple sclerosis," Steinberg said. "To my knowledge, nobody had looked at concentrations of alpha-B-crystallin after a stroke, either in people or in an experimental animal model before."

So, along with first authors Ahmet Arac, MD, a postdoctoral scholar in Steinberg's lab, and Steinman's former graduate student Sarah Brownell, PhD, Steinberg and Steinman turned to a standard animal model: the laboratory mouse. They found that, in mice bioengineered to lack alpha-B-crystallin, experimentally induced stroke lesions were more massive than those induced in otherwise genetically similar mice whose cells were capable of making the protein. The alpha-B-crystallin-deficient mice had worse neurological function after the stroke than did the normal mice.

The researchers also found that supplying synthetic alpha-B-crystallin to the deficient mice reduced brain-lesion sizes after a stroke, even when the substance was administered 12 hours after the stroke was induced. And they saw elevated alpha-B-crystallin levels in blood plasma from both human patients and mice after a stroke. (The human samples were obtained from study co-author Gregory Albers, MD, the Coy Foundation Professor of Neurology and Neurological Sciences and the director of the Stanford Stroke Center).

"In younger patients, the larger the stroke, the higher the concentration of alpha-B-crystallin," said Steinberg. Interestingly, increased alpha-B-crystallin levels were not detected in plasma from patients over the age of 80, whose strokes typically have worse consequences than those affecting younger patients.

Finally, the investigators demonstrated that alpha-B-crystallin-treated mice produce fewer inflammatory immune-signaling molecules and more anti-inflammatory ones than untreated mice.

At the doses given to the mice in this study, alpha-B-crystallin appeared to be nontoxic. "This is a naturally occurring molecule the body is already producing, although maybe just not enough of it," said Steinberg. "We're just supplementing it." If further studies by other labs and in other models confirm and extend the findings, alpha-B-crystallin may be an excellent candidate for clinical trials in stroke, Steinman and Steinberg both said.

"This is the first demonstration of an efficacious brain-protecting agent that targets the inflammatory aspect of stroke in a novel way, and it can be given at quite a delay," said Thomas Carmichael, MD, PhD, professor and vice chair of neurology at the David Geffen School of Medicine at UCLA. Carmichael, a stroke expert, did not participate in the study but is familiar with its methodology and results. "Tissue plasminogen activator has a fairly narrow risk-to-benefit ratio. The longer you wait, the more likely it is to stimulate a hemorrhage."

Email or share this story:

Wednesday, August 10, 2011

Fool's gold gives scientists priceless insight into Earth's evolution

ScienceDaily (July 23, 2011) — Fool's gold is providing scientists with valuable insights into a turning point in Earth's evolution, which took place billions of years ago.See Also:Earth & ClimateGeologyEarth ScienceAtmosphereFossils & RuinsOrigin of LifeEarly ClimateEvolutionReferenceAtmospheric chemistryPrecambrianEarth's atmospherePermian-Triassic extinction event

Scientists are recreating ancient forms of the mineral pyrite -- dubbed fool's gold for its metallic lustre -- that reveal details of past geological events.

Detailed analysis of the mineral is giving fresh insight into Earth before the Great Oxygenation Event, which took place 2.4 billion years ago. This was a time when oxygen released by early forms of bacteria gave rise to new forms of plant and animal life, transforming Earth's oceans and atmosphere.

Studying the composition of pyrite enables a geological snapshot of events at the time when it was formed. Studying the composition of different forms of iron in fool's gold gives scientists clues as to how conditions such as atmospheric oxygen influenced the processes forming the compound.

The latest research shows that bacteria -- which would have been an abundant life form at the time -- did not influence the early composition of pyrite. This result, which contrasts with previous thinking, gives scientists a much clearer picture of the process.

More extensively, their discovery enables better understanding of geological conditions at the time, which informs how the oceans and atmosphere evolved.

The research, funded by the Natural Environment Research Council and the Edinburgh Collaborative of Subsurface Science and Engineering, was published in Science.

Dr Ian Butler, who led the research, said: "Technology allows us to trace scientific processes that we can't see from examining the mineral composition alone, to understand how compounds were formed. This new information about pyrite gives us a much sharper tool with which to analyse the early evolution of the Earth, telling us more about how our planet was formed."

Dr Romain Guilbaud, investigator on the study, said: "Our discovery enables a better understanding of how information on the Earth's evolution, recorded in ancient minerals, can be interpreted."

Email or share this story:

Wednesday, August 3, 2011

Life scientists use novel technique to produce genetic map for African Americans

ScienceDaily (July 23, 2011) — UCLA life scientists and colleagues have produced one of the first high-resolution genetic maps for African American populations. A genetic map reveals the precise locations across the genome where DNA from a person's father and mother have been stitched together through a biological process called "recombination." This process results in new genetic combinations that are then passed on to the person's children.See Also:Health & MedicineGenesHuman BiologySickle Cell AnemiaPersonalized MedicineGene TherapyDiseases and ConditionsReferenceGeneticsHuman Genome ProjectMutationEpidemiology

The new map will help disease geneticists working to map genetic diseases in African Americans because it provides a more accurate understanding of recombination rates among that population, said the senior author of the research, John Novembre, a UCLA assistant professor of ecology and evolutionary biology and of bioinformatics. The map could help scientists learn the roots of these diseases and discover genes that play a key role in them.

The study was published July 20 in the online version of the journal Nature Genetics and will be published in the print edition at a later date.

"Research aimed at finding disease variants will be improved by this tool, which could lead to better medications to help ameliorate the effects of those disease variants," Novembre said. "Health researchers can use a recombination map to refine where a disease gene might be."

Prior to this research, which was conducted by scientists from seven institutions, recombination had mainly been studied in European populations.

"Now we have a map for African Americans that researchers can use as a tool, instead of using a European map or an African map," said Novembre, a member of UCLA's Interdepartmental Program in Bioinformatics.

A second, independent study, led by David Reich at Harvard University and Simon Myers at Oxford University, used a similar approach to infer an African American recombination map. That research was published this week in Nature.

"While recombination rates between populations are very similar when you look at the broadest scales of the genome, we start to see variation in recombination between populations when we zoom in," said Daniel Wegmann, a UCLA postdoctoral scholar in Novembre's laboratory and the lead author of the study. "There are clear differences in recombination between Africans and Europeans, and African Americans tend to have a map that is a mixture between the African and European map, reflecting the mixture that took place between these two groups.

"If the position of a mutation is unknown and you want to pinpoint a gene linked to a disease, then recombination is important to help reveal in what region the gene lies," Wegmann said.

The mixture of African and European ancestry typical in the DNA of African Americans is reflected in recombination rates, Novembre said.

"No high-resolution recombination map has been inferred before for populations where the individuals have ancestry from different parts of the globe," Novembre said. "African Americans represent a unique combination of African and European ancestry. We found that if you know an African recombination rate for one region of the genome and you know the European rate, the African American rate sits about 80 percent of the way between the two. That is interesting, because the ancestry of African American DNA, on average, is 80 percent from African ancestral sources and 20 percent from European ancestral sources. The recombination rate reflects the ancestry."

The life scientists used an innovative method involving population genetic models in which they scanned the individual genomes of 2,565 African Americans, as well as 299 African Caribbeans, to study where in the genome each had African ancestry, where they had European ancestry, and where the "switch points" were that mark the location where the ancestry of a DNA segment changes.

Novembre and colleagues studied the ancestry of DNA segments to reconstruct where recombinations have occurred.

"The key is to uncover the ancestry of each segment of the genome," Novembre said. "Switch points enable us to identify recombination 'hot spots,' where recombination rates are high."

Explaining recombination, Novembre said, "When we pass on DNA to our children, we stitch together the DNA we received from our mother and father. The resulting DNA alternates between DNA from your mother and from your father, and the recombination points are the boundaries. Those points could be chosen uniformly across the whole chromosome, but studies have found that recombinations occur in some locations in the chromosome more than in others. Locations in the chromosome have particular recombination rates -- the rate at which break points occur in that location.

"It is difficult to identify, by studying chromosomes directly, where the stitch points are between maternal and paternal DNA," he said. "In individuals of mixed ancestry, however, such as African Americans and African Caribbeans, we can identify switch points between African ancestry and European ancestry. These switch points mark locations where recombinations have occurred at some point in the past."

"There are regions of our map that differ from what we would expect," Wegmann said. "We see locations where there are deficiencies in recombination, and they line up with the locations of mutations that rearrange the genome and flip a piece of DNA to invert it. When you have a normal copy of the DNA and an inverted copy of the DNA, one from your mother and one from your father, this inversion suppresses recombination."

Of some 3 billion base pairs in a person's genome, the scientists were able to resolve recombination rates down to 50,000 base pairs of the DNA -- an impressive figure.

Comparing this African American recombination map with that of other populations enables researchers to locate recombination hot spots, which have highly elevated rates of recombination.

In addition to the applications for disease mapping, the research provides broad insights into the fundamental biological process of recombination.

"We want to learn how recombination rates vary across the genome," Novembre said.

Nelson Freimer, director of the UCLA Center for Neurobehavioral Genetics and a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, is a principal investigator on the research, along with Novembre and Wegmann, and helped to organize the collaborative effort to bring together the large sample used in the study.

The effort was made possible by the cooperation of investigators from five large consortia: the Genetic Study of Atheroscleoris Risk (GeneSTAR) consortium; the Genetic Network of Arteriopathy (GENOA) consortium; the Chicago Asthma Genetics (CAG) and the Collaborative Study on the Genetics of Asthma (CSGA) consortia; the Genetic Research on Asthma in the Africa Diaspora (GRAAD) consortium; and the Severe Asthma Research Program (SAARP).

The consortia were funded by the STAMPEED (SNP Typing for Association with Multiple Phenotypes from Existing Epidemiological Data) program run by the National Heart, Lung and Blood Institute of the National Institutes of Health. Novembre's research was also funded by the Searle Foundation.

Email or share this story: